Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
20.5.2021 00:14:00 EEST | Business Wire | Press release
Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021.
“We look forward to presenting data from across Incyte’s oncology portfolio and partner programs at this year’s ASCO Annual Meeting,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Data being presented during this congress, including new three-year data from the L-MIND study of tafasitamab in relapsed or refractory diffuse large B-cell lymphoma as well as results of the OPTIC study of ponatinib in chronic phase-chronic myeloid leukemia, underscore our continued focus on advancing science to help meet patients’ needs.”
Key abstracts accepted by ASCO include:
Oral Presentations
Ponatinib
OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)1 (Abstract #7000. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.)
Poster Discussions
Tafasitamab
Long-Term Analyses from L-MIND, a Phase 2 Study of Tafasitamab (MOR208) Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)2 (Abstract #7513. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
Capmatinib
Capmatinib in MET Exon 14-Mutated, Advanced NSCLC: Updated Results from the GEOMETRY Mono-1 Study3 (Abstract #9020. Session: Lung Cancer—Non-Small Cell Metastatic.)
ePosters
Capmatinib
Capmatinib Efficacy in Patients with NSCLC Identified as METex14 Using an NGS-Based Liquid Biopsy Assay: Results from the GEOMETRY Mono-1 Study3 (Abstract #9111. Session: Lung Cancer—Non-Small Cell Metastatic.)
Patient-Reported Outcomes in Capmatinib-Treated Patients with METex14-Mutated Advanced NSCLC: Results from the Phase 2 GEOMETRY Mono-1 Study3 (Abstract #9056. Session: Lung Cancer—Non-Small Cell Metastatic.)
Phase 1b/2 Study of Capmatinib Plus Gefitinib in Patients with EGFR-Mutated, MET-Dysregulated Non–Small Cell Lung Cancer who Received Prior Therapy: Final Overall Survival and Safety3 (Abstract #9048. Session: Lung Cancer—Non-Small Cell Metastatic.)
Pemigatinib
Pemigatinib for Previously Treated Locally Advanced/Metastatic Cholangiocarcinoma (CCA): Update of FIGHT-202 (Abstract #4086. Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary.)
Retifanlimab
Phase 2 Study of Retifanlimab (INCMGA00012) in Patients (Pts) with Selected Solid Tumors (POD1UM-203) (Abstract #2571. Session: Developmental Therapeutics—Immunotherapy.)
Ruxolitinib-Parsaclisib Combination Studies
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naïve Myelofibrosis (Abstract #TPS7058. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.)
Tafasitamab
A Phase 3 Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) (Abstract #TPS7568. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
First-MIND: A Phase 1b, Open-Label, Randomized Study to Assess Safety of Tafasitamab (tafa) or Tafa + Lenalidomide (LEN) in Addition to R‑CHOP in Patients with Newly Diagnosed DLBCL2 (Abstract #7540. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
For full session details and data presentation listings, please see the ASCO21 online program at https://meetinglibrary.asco.org. Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, June 4, 2021 at 9:00 a.m. ET.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s or partner company’s ongoing clinical development pipeline, and whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain and other third-party providers, and development and discovery operations; determinations made by the FDA and other regulatory authorities outside of the United States; the Company’s dependence on its relationships with its collaboration partners; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2020 and the quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.
1 Takeda-sponsored abstract.
2 MorphoSys-sponsored abstract.
3 Novartis-sponsored abstract.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005952/en/
Contact information
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Builds on 80MW of C&I Solar Growth in Czechia with GO Optimized ESS for Residential1.10.2026 07:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company will showcase the Tigo GO Optimized Energy Storage Solution (ESS) at Smart Energy Forum (SEF) 2026 in Prague, building on strong adoption of Tigo technology across the Czech commercial and industrial (C&I) solar market. Since 2024, Czech installers have deployed Tigo products in approximately 80MW of C&I systems, providing a solid foundation for Tigo to expand its residential solar-plus-storage offering. Across residential, small commercial, and larger C&I applications, installers in Czechia have deployed approximately 276MW of Tigo systems since 2024. At the heart of the Tigo showcase will be the Tigo GO Optimized ESS, featuring the expanded storage capacity of the new GO Battery, plus e-mobility and heat-pump integration, with intelligent system management through the Tigo Energy Intelligence monitoring platform. Visitors can
Umios and Wah Kong Complete Strategic Pet Food Joint Venture in Southeast Asia; Japan Corporate Advisory Institute Advised on the Transaction1.10.2026 03:00:00 EEST | Press release
Umios Corporation (TOKYO Prime: 1333; formerly Maruha Nichiro) and Wah Kong Corporation have completed the establishment of a strategic joint venture centered on Pet World International Sdn. Bhd. (“PWI”), one of Malaysia’s leading pet food companies. Under the transaction, Umios invested approximately JPY 11.4 billion to acquire a 51% interest in PWI through a newly established holding company. PWI holds the No. 2 share of Malaysia’s pet food market — No. 1 among local companies (NielsenIQ) — and operates the country’s only BRC-certified pet food plant. The company has approximately 350 employees, sells through more than 10,000 physical stores and its own e-commerce channels, and posted consolidated sales of approximately JPY 12.4 billion in the year ended September 2025. The joint venture combines Umios’s strengths in wet pet food with PWI’s dry-food capabilities, creating comprehensive coverage across dogs and cats, wet and dry. The partnership is expected to integrate the parties’ s
INNIO Completes Acquisition of Enerflex APAC Aftermarket Operations1.10.2026 00:02:00 EEST | Press release
INNIO N.V. (Nasdaq: INIO) today announced the completion of its acquisition of Enerflex Ltd.’s aftermarket business operations in Australia, Thailand, and Indonesia. The transaction strengthens INNIO’s presence in the Asia-Pacific (APAC) region and expands its ability to serve customers through enhanced local service capabilities and greater customer proximity. The acquired business operates principally across three countries and eight locations and brings extensive workshop and office facilities, a highly experienced workforce, and a strong installed base supported by long-term service agreements with major oil and gas companies in the region. Through the transaction, INNIO further strengthens its ability to deliver responsive, high-quality service and lifecycle support to customers throughout APAC. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Textron Aviation Builds Future Workforce With Kansas’ First Aviation Youth Apprenticeship Program.30.9.2026 21:55:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, is further bolstering the company’s efforts to build the next generation workforce as the first aviation company in Kansas to offer state-registered youth apprenticeships through the Kansas Office of Apprenticeships. The program expands career opportunities for high school students beginning at age 16 by providing paid, hands-on learning experiences that develop industry knowledge and career-ready skills while they complete their education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930818829/en/ Textron Aviation builds future workforce with Kansas’ first aviation youth apprenticeship program (Photo Credit: Textron Aviation). Textron Aviation is launching three state-registered youth apprenticeship programs to include: Airframe & Powerplant (A&P) in collaboration with WSU Tech in Wichita, Kansas Avionics in collaboration with WSU Tech in Wichita, Kansas Engine
Thales and Landis+Gyr Enable Smarter, Remotely Managed Connectivity for Smart Meter Fleets30.9.2026 21:00:00 EEST | Press release
As utilities modernize their infrastructure, smart meters are becoming an increasingly important part of the connected energy ecosystem. Landis+Gyr serves more than 2,000 utilities worldwide and has more than 180 million connected intelligent devices in the field. In North America alone, the installed base of smart electricity meters is expected to grow from 152.4 million in 2024 to 180.9 million by 2030, according to Berg Insight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930715193/en/ This is where the latest generation of Thales eSIM technology is supporting the increasing need for cellular IoT. Compliant with the GSMA's SGP.32 specification, it enables remotely managing connectivity on IoT devices, allowing network profiles to be provisioned, changed or managed over the air. By reducing reliance on physical SIM replacement and supporting interoperability across the IoT ecosystem, it provides a foundation for more
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom